Acute lung injury (ALI) is an inflammatory pulmonary disease mainly caused by infection. It can progress to the life-threatening condition acute respiratory distress syndrome (ARDS). ALI/ARDS account for a high mortality rate of about 40%. Elucidating the mechanisms behind ALI/ARDS is crucial for developing new therapeutics.

ALK5 mediates the core profibrotic TGF-β signaling cascade that promotes fibroblast activation, myofibroblast differentiation and extracellular matrix production, ultimately leading to persistent tissue remodeling and lung fibrosis.

Molecular subtyping of disease is typically associated with cancer. Now, researchers at the University of Cambridge are applying it to infections. Some patients with severe pneumonia progress in different ways. Predicting their trajectories could help tailor treatments and prevent fatal outcomes. To do this, the scientists analyzed bronchoalveolar fluid from several patient cohorts and identified three biological pneumotypes based on which cells are present, which genes are active, and which inflammatory proteins are produced.

Idiopathic pulmonary fibrosis (IPF), a chronic, progressive disease of unknown etiology, is the most common and fatal interstitial lung disease. Currently available treatments for IPF, such as pirfenidone and nintedanib, can slow disease progression and reduce mortality in patients who can tolerate them. However, these drugs frequently cause significant side effects and have been unable to improve quality of life in pivotal trials, which highlights the critical need for discovering novel IPF treatment strategies.

The microbiome and a frontline innate antimicrobial sensor, Toll-like receptor 5 (TLR5), play an essential role in the development of idiopathic pulmonary fibrosis (IPF). A scientific collaboration led by researchers at the National Institute of Environmental Health Sciences has revealed how TLR5 protects against fibrosis through its ability to modulate the lung microbiome. Their study also shows that activating TLR5 protects against fibrosis and corrects pulmonary dysbiosis.

Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that autoimmunity might underlie the persistent neurological symptoms seen in long COVID, researchers at Yale University and Mount Sinai now reinforce this hypothesis. SARS-CoV-2 infection appears to trigger an autoimmune mechanism that drives chronic pain, fatigue and cognitive impairment in some patients.